A Study of Intravenous Mircera in Participants With Chronic Renal Anemia Who Are on Dialysis
Status:
Completed
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
This single-arm study will assess the efficacy and safety of monthly administration of
intravenous methoxy polyethylene glycol-epoetin beta (CERA/Mircera) for the maintenance of
hemoglobin (Hb) levels in participants on dialysis with chronic renal anemia in routine
clinical practice in Hungary. Participants currently receiving maintenance treatment with
intravenous epoetin or darbepoetin will receive monthly injections of Mircera, with the
starting dose derived from the erythropoiesis-stimulating agent (ESA) dose they had been
receiving.